Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF).

Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 8604127 Publication Model: eCollection Cited Medium: Internet ISSN: 1875-8630 (Electronic) Linking ISSN: 02780240 NLM ISO Abbreviation: Dis Markers Subsets: MEDLINE

Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-

Biomarkers/*blood ; Heart Failure/*blood ; Heart Failure/*physiopathology ; Procalcitonin/*blood; Aged ; Case-Control Studies ; Chronic Disease ; Female ; Heart Failure/mortality ; Heart Failure, Systolic/blood ; Heart Failure, Systolic/physiopathology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; ROC Curve

Introduction: Procalcitonin (PCT) is an excellent marker of sepsis but was not extensively studied in cardiology. The present study investigated PCT plasma concentration in patients with chronic heart failure with reduced ejection fraction (HFrEF) and its prognostic value during 24-month follow-up.
Material and Methods: Study group consisted of 130 patients with HFrEF (LVEF ≤ 45%) and 32 controls. PCT level was assessed on admission in all patients. Telephone follow-up was performed every three months over a period of 2 years. Endpoints were death of all causes and readmission for HFrEF exacerbation.
Results: HFrEF patients had significantly higher PCT concentration than controls (166.95 versus 22.15 pg/ml; p < 0.001). Individuals with peripheral oedema had increased PCT comparing to those without oedema (217.07 versus 152.12 pg/ml; p < 0.02). In ROC analysis, PCT turned out to be a valuable diagnostic marker of HFrEF (AUC 0.91; p < 0.001). Kaplan-Meier survival curves revealed that patients with PCT in the 4th quartile had significantly lower probability of survival than those with PCT in the 1st and 2nd quartiles. In univariate, but not multivariate, analysis, procalcitonin turned out to be a significant predictor of death during 24-month follow-up. (HR 1.002; 95% CI 1.000-1.003; p < 0.03).
Conclusions: Elevated PCT concentration may serve as another predictor of worse outcome in patients with HFrEF.

Circulation. 1994 Jul;90(1):195-203. (PMID: 8025996)
Eur J Heart Fail. 2012 Mar;14(3):278-86. (PMID: 22302662)
Stroke. 2016 Jul;47(7):1714-9. (PMID: 27197849)
Cytokine. 2010 Mar;49(3):264-8. (PMID: 20005739)
Crit Care. 2014 Jan 06;18(1):R4. (PMID: 24393388)
Eur J Intern Med. 2015 Jan;26(1):42-8. (PMID: 25592074)
Biomark Med. 2016 Jul;10(7):733-42. (PMID: 27355366)
Circulation. 1996 Jun 1;93(11):1963-9. (PMID: 8640969)
Biomark Med. 2015;9(7):651-9. (PMID: 26174839)
Curr Opin Clin Nutr Metab Care. 2008 Sep;11(5):632-9. (PMID: 18685461)
Am Heart J. 1997 Sep;134(3):442-9. (PMID: 9327700)
Circulation. 1995 Sep 15;92(6):1479-86. (PMID: 7664430)
J Am Coll Cardiol. 2009 Mar 24;53(12):1013-20. (PMID: 19298913)
Congest Heart Fail. 2006 Nov-Dec;12(6):324-8. (PMID: 17170586)
Am Heart J. 2007 Jun;153(6):1048-55. (PMID: 17540208)
Lupus. 2016 Dec;25(14):1625-1626. (PMID: 27216419)
Lancet. 1993 Feb 27;341(8844):515-8. (PMID: 8094770)
Acta Cardiol. 2015 Aug;70(4):473-8. (PMID: 26455251)
J Clin Endocrinol Metab. 2009 Mar;94(3):861-8. (PMID: 19088163)
JACC Heart Fail. 2016 Mar;4(3):220-7. (PMID: 26682791)

0 (Biomarkers)
0 (Procalcitonin)

Date Created: 20180925 Date Completed: 20190102 Latest Revision: 20220408

20240105

PMC6136577

10.1155/2018/9542784

30245756